Prime Medicine Announces Pricing of Public Offering of Common Stock

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on gene editing therapies, announced a public offering of 35.7 million shares at $3.50 per share, expected to raise approximately $125 million. The offering is expected to close on November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs serving as joint book-running managers.